APVO Latest Press Releases

-- October 14, 2026 --

Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting ACCESS Newswire 8:46 AM

-- September 24, 2026 --

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development ACCESS Newswire 8:05 AM

-- September 3, 2026 --

Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML ACCESS Newswire 8:05 AM

-- August 14, 2026 --

Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results ACCESS Newswire 8:05 AM

-- August 13, 2026 --

Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds ACCESS Newswire 4:05 PM

-- August 12, 2026 --

Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds ACCESS Newswire 9:33 AM

-- July 27, 2026 --

Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone ACCESS Newswire 8:05 AM

-- June 30, 2026 --

Aptevo Secures $1.5 Million Non-Dilutive Research Grant From the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors ACCESS Newswire 8:05 AM

-- May 28, 2026 --

Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer ACCESS Newswire 8:05 AM

-- May 27, 2026 --

Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing ACCESS Newswire 8:05 AM

Market Data Delayed 15 Minutes